|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Woodman CB, Collins SI and Young LS: The
natural history of cervical HPV infection: Unresolved issues. Nat
Rev Cance. 7:11–22. 2007. View
Article : Google Scholar
|
|
4
|
Boshart M, Gissmann L, Ikenberg H,
Kleinheinz A, Scheurlen W and zur Hausen H: A new type of
papillomavirus DNA, its presence in genital cancer biopsies and in
cell lines derived from cervical cancer. EMBO J. 3:1151–1157. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Durst M, Gissmann L, Ikenberg H and zur
Hausen H: A papillomavirus DNA from a cervical carcinoma and its
prevalence in cancer biopsy samples from different geographic
regions. Proc Natl Acad Sci USA. 80:3812–3815. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Narisawa-Saito M and Kiyono T: Basic
mechanisms of high-risk human papillomavirus-induced
carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci.
98:1505–1511. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moody CA and Laimins LA: Human
papillomavirus oncoproteins: Pathways to transformation. Nat Rev
Cancer. 10:550–560. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Da Silva DM, Eiben GL, Fausch SC,
Wakabayashi MT, Rudolf MP, Velders MP and Kast WM: Cervical cancer
vaccines: Emerging concepts and developments. J Cell Physiol.
186:169–182. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jinek M, Chylinski K, Fonfara I, Hauer M,
Doudna JA and Charpentier E: A programmable dual-RNA-guided DNA
endonuclease in adaptive bacterial immunity. Science. 337:816–821.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu PD, Lander ES and Zhang F: Development
and applications of CRISPR-Cas9 for genome engineering. Cell.
157:1262–1278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mueller C and Flotte TR: Clinical gene
therapy using recombinant adeno-associated virus vectors. Gene
Ther. 15:858–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grieger JC and Samulski RJ:
Adeno-associated virus vectorology, manufacturing, and clinical
applications. Methods Enzymol. 507:229–254. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu Z, Asokan A and Samulski RJ:
Adeno-associated virus serotypes: Vector toolkit for human gene
therapy. Mol Ther. 14:316–327. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato N, Saga Y, Uchibori R, Tsukahara T,
Urabe M, Kume A, Fujiwara H, Suzuki M, Ozawa K and Mizukami H:
Eradication of cervical cancer in vivo by an AAV vector that
encodes shRNA targeting human papillomavirus type 16 E6/E7. Int J
Oncol. 52:687–696. 2018.PubMed/NCBI
|
|
15
|
Urabe M, Hasumi Y, Ogasawara Y, Matsushita
T, Kamoshita N, Nomoto A, Colosi P, Kurtzman GJ, Tobita K and Ozawa
K: A novel dicistronic AAV vector using a short IRES segment
derived from hepatitis C virus genome. Gene. 200:157–162. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsushita T, Elliger S, Elliger C,
Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y and Colosi P:
Adeno-associated virus vectors can be efficiently produced without
helper virus. Gene Ther. 5:938–945. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mochizuki S, Mizukami H, Kume A, Muramatsu
S, Takeuchi K, Matsushita T, Okada T, Kobayashi E, Hoshika A and
Ozawa K: Adenoassociated virus (AAV) vector-mediated liver- and
muscle-directed transgene expression using various kinds of
promoters and serotypes. Gene Ther Mol Biol. 8:9–18. 2004.
|
|
18
|
Xiao W, Chirmule N, Berta SC, McCullough
B, Gao G and Wilson JM: Gene therapy vectors based on
adeno-associated virus type 1. J Virol. 73:3994–4003.
1999.PubMed/NCBI
|
|
19
|
Ishiwata A, Mimuro J, Mizukami H,
Kashiwakura Y, Takano K, Ohmori T, Madoiwa S, Ozawa K and Sakata Y:
Liver-restricted expression of the canine factor VIII gene
facilitates prevention of inhibitor formation in factor
VIII-deficient mice. J Gene Med. 11:1020–1029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu C, Zhang Y, Yao S and Wei Y: A PCR
based protocol for detecting indel mutations induced by TALENs and
CRISPR/Cas9 in zebrafish. PLoS One. 9:e982822014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong JY, Fan PD and Frizzell RA:
Quantitative analysis of the packaging capacity of recombinant
adeno-associated virus. Hum Gene Ther. 7:2101–2112. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech
L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, et
al: CRISPR-Cas9 knockin mice for genome editing and cancer
modeling. Cell. 159:440–455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Crook T, Wrede D, Tidy JA, Mason WP, Evans
DJ and Vousden KH: Clonal p53 mutation in primary cervical cancer:
Association with human-papillomavirus-negative tumours. Lancet.
339:1070–1073. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paquette RL, Lee YY, Wilczynski SP,
Karmakar A, Kizaki M, Miller CW and Koeffler HP: Mutations of p53
and human papillomavirus infection in cervical carcinoma. Cancer.
72:1272–1280. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pillay S, Meyer NL, Puschnik AS, Davulcu
O, Diep J, Ishikawa Y, Jae LT, Wosen JE, Nagamine CM, Chapman MS
and Carette JE: An essential receptor for adeno-associated virus
infection. Nature. 530:108–112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang
C, Wang L, Jiang X, Shen H, He D, et al: Disruption of HPV16-E7 by
CRISPR/Cas system induces apoptosis and growth inhibition in HPV16
positive human cervical cancer cells. Biomed Res Int.
2014:6128232014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu L, Wang X, Zhu D, Ding W, Wang L, Zhang
C, Jiang X, Shen H, Liao S, Ma D, et al: Disruption of human
papillomavirus 16 E6 gene by clustered regularly interspaced short
palindromic repeat/Cas system in human cervical cancer cells. Onco
Targets Ther. 8:37–44. 2014.PubMed/NCBI
|
|
29
|
Zhen S, Hua L, Takahashi Y, Narita S, Liu
YH and Li Y: In vitro and in vivo growth suppression of human
papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9.
Biochem Biophys Res Commun. 450:1422–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kennedy EM, Kornepati AV, Goldstein M,
Bogerd HP, Poling BC, Whisnant AW, Kastan MB and Cullen BR:
Inactivation of the human papillomavirus E6 or E7 gene in cervical
carcinoma cells by using a bacterial CRISPR/Cas RNA-guided
endonuclease. J Virol. 88:11965–11972. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhen S, Lu JJ, Wang LJ, Sun XM, Zhang JQ,
Li X, Luo WJ and Zhao L: In vitro and in vivo synergistic
therapeutic effect of cisplatin with human papillomavirus16 E6/E7
CRISPR/Cas9 on cervical cancer cell line. Transl Oncol. 9:498–504.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sevin BU, Nadji M, Averette HE, Hilsenbeck
S, Smith D and Lampe B: Microinvasive carcinoma of the cervix.
Cancer. 70:2121–2128. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Massad LS, Einstein MH, Huh WK, Katki HA,
Kinney WK, Schiffman M, Solomon D, Wentzensen N and Lawson HW: 2012
ASCCP Consensus Guidelines Conference: 2012 updated consensus
guidelines for the management of abnormal cervical cancer screening
tests and cancer precursors. Obstet Gynecol. 121:829–846. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bevis KS and Biggio JR: Cervical
conization and the risk of preterm delivery. Am J Obstet Gynecol.
205:19–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Melnikow J, McGahan C, Sawaya GF, Ehlen T
and Coldman A: Cervical intraepithelial neoplasia outcomes after
treatment: Long-term follow-up from the British Columbia Cohort
Study. J Natl Cancer Inst. 101:721–728. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ran FA, Cong L, Yan WX, Scott DA,
Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, et
al: In vivo genome editing using Staphylococcus aureus Cas9.
Nature. 520:186–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
